BR0314777A - Modified Release Dosage Forms - Google Patents

Modified Release Dosage Forms

Info

Publication number
BR0314777A
BR0314777A BR0314777-0A BR0314777A BR0314777A BR 0314777 A BR0314777 A BR 0314777A BR 0314777 A BR0314777 A BR 0314777A BR 0314777 A BR0314777 A BR 0314777A
Authority
BR
Brazil
Prior art keywords
dosage form
liquid medium
active ingredient
release
core
Prior art date
Application number
BR0314777-0A
Other languages
Portuguese (pt)
Inventor
Shun-Por Li
Der-Yang Lee
Gerard P Mcnally
Daniel Mcteigue
Narendra Parikh
Harry S Sowden
David Wynn
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/031163 external-priority patent/WO2003026627A1/en
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Priority claimed from PCT/US2003/008891 external-priority patent/WO2004028504A1/en
Publication of BR0314777A publication Critical patent/BR0314777A/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMAS DE DOSAGEM DE LIBERAçãO MODIFICADA". A presente invenção refere-se a uma forma de dosagem compreende: (a) pelo menos um ingrediente ativo; (b) um núcleo tendo uma superfície externa; e (c) uma cobertura externa que está presente sobre pelo menos uma parte da superfície externa do núcleo, em que pelo menos uma parte da cobertura externa é semipermeável, de modo tal que o meio líquido difunda-se através da cobertura externa ou da parte da cobertura externa semipermeável até o núcleo, devido à osmose. A cobertura externa também proporciona a distribuição do ingrediente ativo para um meio líquido fora da cobertura externa, após o contato da forma de dosagem com o meio líquido. A forma de dosagem distribui um ou mais ingredientes ativos em um modo controlado com o contato da forma de dosagem com um meio líquido. A forma de dosagem pode ser empregada para proporcionar uma liberação por ruptura do ingrediente ativo, ou para proporcionar a liberação do ingrediente ativo em uma taxa de liberação ascendente durante um período de tempo prolongado, com o contato da forma de dosagem com um meio líquido."MODIFIED RELEASE DOSAGE FORMS". The present invention relates to a dosage form comprising: (a) at least one active ingredient; (b) a core having an outer surface; and (c) an outer casing which is present on at least a portion of the outer surface of the core, wherein at least a portion of the outer casing is semipermeable, such that the liquid medium diffuses through the outer casing or the casing portion. from the semipermeable outer covering to the core due to osmosis. The outer shell also provides for the distribution of the active ingredient to a liquid medium outside the outer shell after contact of the dosage form with the liquid medium. The dosage form delivers one or more active ingredients in a controlled manner upon contact of the dosage form with a liquid medium. The dosage form may be employed to provide rupture release of the active ingredient, or to provide release of the active ingredient at an upward release rate over an extended period of time by contacting the dosage form with a liquid medium.

BR0314777-0A 2002-09-28 2003-03-21 Modified Release Dosage Forms BR0314777A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/US2002/031163 WO2003026627A1 (en) 2001-09-28 2002-09-28 Composite dosage forms
PCT/US2002/031024 WO2003026625A1 (en) 2001-09-28 2002-09-28 Modified release dosage forms
PCT/US2002/031129 WO2003026630A1 (en) 2001-09-28 2002-09-28 Dosage forms having an inner core and outer shell with different shapes
PCT/US2002/031117 WO2003026629A2 (en) 2001-09-28 2002-09-28 Modified release dosage forms
PCT/US2002/031062 WO2003026626A2 (en) 2001-09-28 2002-09-28 Modified release dosage forms
PCT/US2003/008891 WO2004028504A1 (en) 2002-09-28 2003-03-21 Modified release dosage forms

Publications (1)

Publication Number Publication Date
BR0314777A true BR0314777A (en) 2005-07-26

Family

ID=34271652

Family Applications (5)

Application Number Title Priority Date Filing Date
BR0314547-6A BR0314547A (en) 2002-09-28 2003-03-21 Immediate release dosage form comprising a shell having openings therein
BR0314781-9A BR0314781A (en) 2002-09-28 2003-03-21 Polymer composition and dosage forms comprising the same
BR0314787-8A BR0314787A (en) 2002-09-28 2003-03-21 Modified Release Dosage Form
BR0314777-0A BR0314777A (en) 2002-09-28 2003-03-21 Modified Release Dosage Forms
BR0314804-1A BR0314804A (en) 2002-09-28 2003-03-21 Modified Release Dosage Form

Family Applications Before (3)

Application Number Title Priority Date Filing Date
BR0314547-6A BR0314547A (en) 2002-09-28 2003-03-21 Immediate release dosage form comprising a shell having openings therein
BR0314781-9A BR0314781A (en) 2002-09-28 2003-03-21 Polymer composition and dosage forms comprising the same
BR0314787-8A BR0314787A (en) 2002-09-28 2003-03-21 Modified Release Dosage Form

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0314804-1A BR0314804A (en) 2002-09-28 2003-03-21 Modified Release Dosage Form

Country Status (8)

Country Link
JP (3) JP2006517183A (en)
CN (3) CN1700908A (en)
AT (1) ATE444739T1 (en)
AU (4) AU2003218359A1 (en)
BR (5) BR0314547A (en)
CA (3) CA2500313C (en)
DE (2) DE60335270D1 (en)
MX (1) MXPA05003283A (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2470463C (en) 2004-06-09 2012-09-18 Lornamead Brands, Inc. Tooth whitening products and methods of making the same
SA07280459B1 (en) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
WO2009153635A1 (en) * 2008-06-19 2009-12-23 University Of Witwatersrand, Johannesburg A chronotherapeutic pharmaceutical dosage form
EP2550960A4 (en) * 2010-03-23 2013-08-28 Lintec Corp Solid preparation
US9693957B2 (en) * 2011-07-08 2017-07-04 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
MX359529B (en) * 2012-02-07 2018-10-01 Mcneil Ppc Inc Rapidly disintegrating coated tablets.
US9693962B2 (en) * 2012-06-05 2017-07-04 Takeda Pharmaceutical Limited Dry-coated tablet
WO2016044704A1 (en) * 2014-09-19 2016-03-24 The Procter & Gamble Company Pulsed release phenylephrine dosage forms
JP2021516697A (en) 2017-12-29 2021-07-08 ラクソン メディカル アーゲーＬａｘｘｏｎ Ｍｅｄｉｃａｌ ＡＧ Drug delivery system
IL310523A (en) * 2021-07-30 2024-03-01 Evecxia Therapeutics Inc 5-hydroxytryptophan gastroretentive dosage forms
CN115295864B (en) * 2021-11-09 2023-08-11 深圳市德方创域新能源科技有限公司 Positive electrode lithium supplementing additive and preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007470A1 (en) * 1992-09-30 1994-04-14 Pfizer Inc. Article containing a core and a coating having a non constant thickness
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
DE4431653C2 (en) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Coated tablet for the controlled release of active substances, a process for their preparation and their use
IT1282576B1 (en) * 1996-02-06 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET SUITABLE TO GIVE THE ACTIVE SUBSTANCE IN SUBSEQUENT AND PREDETERMINABLE TIMES
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
JPWO2001078681A1 (en) * 2000-04-17 2004-01-08 山之内製薬株式会社 Drug delivery system and method for avoiding pharmacokinetic drug interaction
WO2002064121A1 (en) * 2001-02-13 2002-08-22 Astrazeneca Ab Novel modified released formulation

Also Published As

Publication number Publication date
JP2006517183A (en) 2006-07-20
BR0314787A (en) 2005-07-26
DE60335270D1 (en) 2011-01-20
CN1700908A (en) 2005-11-23
CA2500311A1 (en) 2004-04-08
CN1700907A (en) 2005-11-23
AU2003225944A1 (en) 2004-04-19
BR0314547A (en) 2005-08-09
BR0314804A (en) 2005-08-02
AU2003220472A1 (en) 2004-04-19
BR0314781A (en) 2005-07-26
CA2500312A1 (en) 2004-04-08
JP2006517514A (en) 2006-07-27
AU2003220466A1 (en) 2004-04-19
CA2500313C (en) 2011-06-07
JP2006517182A (en) 2006-07-20
DE60329614D1 (en) 2009-11-19
MXPA05003283A (en) 2005-11-23
AU2003218359A1 (en) 2004-04-19
CN1684671A (en) 2005-10-19
CA2500313A1 (en) 2004-04-08
ATE444739T1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
BR0212946A (en) Modified Release Dosage Forms
BR9814807A (en) Multilayer detergent tablet
BR0314777A (en) Modified Release Dosage Forms
DK1265698T3 (en) Lipid nanocapsules, method of preparation thereof and use as a medicament
SE9500422D0 (en) New oral pharmaceutical dosage forms
CO4520286A1 (en) PROCEDURE FOR PREPARING 1- (2-DEXESOXY-2, 2-DIFLUORO-D-RIBOFURANOSIL) -4-AMINOPYRIMIDIN-2-ONA
BR0111645A (en) Medical Device Surface Treatment
TNSN01123A1 (en) NEW DOSAGE FORMS WITH CONTROLLED RELEASE
BR0114628A (en) Impact applicator microprojection retention member
DE10190550D2 (en) Cosmetic composition
PT797991E (en) FORMULATION WITH PROLONGED LIBERATION CONTAINING VENLAFAXIN
BR0107646A (en) Osmotic device inside an osmotic device
BR0102116A (en) Components for breathing circuits
DK0589893T3 (en) Use of a bacteriocin as an antimicrobial agent for the manufacture of a medicament for the treatment of gastric disorders associated with helicobacter pylori
PT1267832E (en) AUTO-EMULSIFYING SYSTEM OF LIBERATION OF PHARMACO
NO20063178L (en) Progabalinpreparat
DK1091747T3 (en) Use of isoosmotic saline solutions to prevent inflammation
BR0214716A (en) Contraceptives to prevent pregnancy and decrease premenstrual symptoms
BRPI0414305A (en) oral drug delivery system
HUP0203197A2 (en) Use of docetaxel for treating hepatocellular carcinoma
CL2004001421A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM 1,4-DIPIPERIDIN-4-IL-PIPERAZINA; AND ITS USE FOR THE PREVENTION AND / OR TREATMENT OF PAIN.
DK1082962T3 (en) Use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors NF- (K) B
EP1136492A4 (en) Sulfonamide compounds and uses thereof as medicines
WO2002099422A3 (en) Individualization of therapy with alzheimer's disease agents
NO20044463L (en) Improved modified-release preparation

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]